Imagine checking your blood sugar without ever needing a needle or a painful prick. This technology pulls a tiny amount of fluid from just under the skin to measure glucose levels invisibly. It turns a painful daily chore into a simple, painless digital checkup.
Current glucose monitoring is painful and inconvenient, leading many diabetics to ignore prescribed monitoring schedules. This creates a gap in a 16+ billion euro industry where patients avoid the very tools needed to manage their health.
A miniaturized, non-invasive glucose monitoring system (TALISMAN) including the sensor hardware and supporting software.
If you are a medical device company dealing with low patient compliance due to painful testing — this project developed a needle-free monitoring system that removes the pain barrier. This allows users to monitor glucose more consistently, targeting a market of over 2 billion people.
If you are a digital health provider dealing with gaps in patient data — this project developed a non-invasive sensor and software for the TALISMAN device. This enables continuous data flow for AI-driven diabetes prevention without requiring blood draws.
If you are an insurer dealing with the high cost of diabetes care for the 35% of the population at high risk — this project developed a tool to prevent diabetes onset. By making monitoring painless, it encourages early intervention and reduces long-term treatment costs.
Based on available project data, the specific unit price is not mentioned, but the project objective was to make the system affordable for the end user.
The project focused on miniaturizing and optimizing the technology to turn a scientific discovery into an end-user device for a potential market of 2 billion people.
The technology has been invented and patented, and the scientific foundation has been peer-reviewed by the global scientific community.
Clinical tests showed a Mean Absolute Relative Difference (MARD) of 12.9% when comparing interstitial fluid samples to capillary blood glucose samples.
The project ran from February 1, 2022, to January 31, 2024, moving from proof of concept to clinical performance studies.
The project was executed by a single partner, GLUCOMODICUM OY, a Finnish SME. This indicates a highly centralized IP structure where 100% of the industrial development is held by one entity, simplifying licensing but relying on a single company's capacity for commercialization.
Contact GLUCOMODICUM OY in Finland regarding the TALISMAN device
Contact us to explore licensing opportunities for this needle-free glucose monitoring technology.
